| Steven Sorrells Scott, MD | |
|
242 Kings Avenue, Athens, GA 30606 | |
| (706) 475-1950 | |
| Not Available |
| Full Name | Steven Sorrells Scott |
|---|---|
| Gender | Male |
| Speciality | Thoracic Surgery |
| Experience | 35 Years |
| Location | 242 Kings Avenue, Athens, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1306839444 | NPI | - | NPPES |
| 1306839444 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208G00000X | Thoracic Surgery (cardiothoracic Vascular Surgery) | 034241 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Piedmont Home Health | Athens, GA | Home health agency |
| Encompass Health Home Health | Elberton, GA | Home health agency |
| Guardian Home Care Of Central Georgia | Watkinsville, GA | Home health agency |
| Amedisys Home Health Of Covington | Covington, GA | Home health agency |
| Piedmont Athens Regional Medical Center | Athens, GA | Hospital |
| Piedmont Newton Hospital | Covington, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Piedmont Athens Specialty Care Llc | 8820349772 | 99 |
News Archive
The February 2013 issue of the Global Health Diplomacy Network's Health & Foreign Policy Bulletin is now available online.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
Do you have darker skin? If so, skin cancer might not be top of mind as a significant health threat, but beware – just because your skin is darker does not mean you are immune to skin cancer.
The University of Washington and Seattle Cancer Care Alliance (SCCA) partnered to launch UW-OncoPlex - an advanced gene sequencing test to help clinicians treat cancer. The new diagnostic tool is a significant milestone in the development of precision medicine and empowers doctors to predict which treatment therapies will be most effective for an individual patient's cancer.
› Verified 3 days ago
| Entity Name | Piedmont Cardiology Of Atlanta, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275729691 PECOS PAC ID: 0345321691 Enrollment ID: O20080114000153 |
News Archive
The February 2013 issue of the Global Health Diplomacy Network's Health & Foreign Policy Bulletin is now available online.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
Do you have darker skin? If so, skin cancer might not be top of mind as a significant health threat, but beware – just because your skin is darker does not mean you are immune to skin cancer.
The University of Washington and Seattle Cancer Care Alliance (SCCA) partnered to launch UW-OncoPlex - an advanced gene sequencing test to help clinicians treat cancer. The new diagnostic tool is a significant milestone in the development of precision medicine and empowers doctors to predict which treatment therapies will be most effective for an individual patient's cancer.
› Verified 3 days ago
| Entity Name | Athens Regional Specialty Services, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083939136 PECOS PAC ID: 8325162340 Enrollment ID: O20100827000645 |
News Archive
The February 2013 issue of the Global Health Diplomacy Network's Health & Foreign Policy Bulletin is now available online.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
Do you have darker skin? If so, skin cancer might not be top of mind as a significant health threat, but beware – just because your skin is darker does not mean you are immune to skin cancer.
The University of Washington and Seattle Cancer Care Alliance (SCCA) partnered to launch UW-OncoPlex - an advanced gene sequencing test to help clinicians treat cancer. The new diagnostic tool is a significant milestone in the development of precision medicine and empowers doctors to predict which treatment therapies will be most effective for an individual patient's cancer.
› Verified 3 days ago
| Entity Name | Piedmont Athens Specialty Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184130627 PECOS PAC ID: 8820349772 Enrollment ID: O20180917001273 |
News Archive
The February 2013 issue of the Global Health Diplomacy Network's Health & Foreign Policy Bulletin is now available online.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
Do you have darker skin? If so, skin cancer might not be top of mind as a significant health threat, but beware – just because your skin is darker does not mean you are immune to skin cancer.
The University of Washington and Seattle Cancer Care Alliance (SCCA) partnered to launch UW-OncoPlex - an advanced gene sequencing test to help clinicians treat cancer. The new diagnostic tool is a significant milestone in the development of precision medicine and empowers doctors to predict which treatment therapies will be most effective for an individual patient's cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Sorrells Scott, MD 242 Kings Avenue, Athens, GA 30606 Ph: (706) 475-1950 | Steven Sorrells Scott, MD 242 Kings Avenue, Athens, GA 30606 Ph: (706) 475-1950 |
News Archive
The February 2013 issue of the Global Health Diplomacy Network's Health & Foreign Policy Bulletin is now available online.
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from the interim analysis of a dose-ranging Phase 2b study of dupilumab in adult patients with uncontrolled moderate-to-severe asthma. Dupilumab is an investigational therapy blocking IL-4 and IL-13, two cytokines required for the Th2 immune response.
Do you have darker skin? If so, skin cancer might not be top of mind as a significant health threat, but beware – just because your skin is darker does not mean you are immune to skin cancer.
The University of Washington and Seattle Cancer Care Alliance (SCCA) partnered to launch UW-OncoPlex - an advanced gene sequencing test to help clinicians treat cancer. The new diagnostic tool is a significant milestone in the development of precision medicine and empowers doctors to predict which treatment therapies will be most effective for an individual patient's cancer.
› Verified 3 days ago
Dr. Jonathan Trent Magruder, M.D. Thoracic Surgery (Cardiothoracic Vascular Surgery) Medicare: Accepting Medicare Assignments Practice Location: 242 King Avenue, Suite 230, Athens, GA 30606 Phone: 706-475-1700 |